UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 107

Sortiert nach

Cetuximab plus cisplatin–5-fluorouracil versus cisplatin–5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie

Annals of oncology, 2009-10, Vol.20 (10), p.1667-1673

2009

Link zum Volltext

Verfügbarkeit prüfen

Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Annals of oncology, 2012-11, Vol.23 (11), p.2827-2834

2012

Link zum Volltext

Verfügbarkeit prüfen

Multicenter phase II study of oral capecitabine (Xeloda“) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy

Annals of oncology, 2003-08, Vol.14 (8), p.1227-1233

2003

Link zum Volltext

Verfügbarkeit prüfen

A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study

Annals of oncology, 2019-09, Vol.30 (9), p.1487-1495

2019

Link zum Volltext

Verfügbarkeit prüfen

Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts

British journal of cancer, 2011-08, Vol.105 (4), p.505-512

2011

Link zum Volltext

Verfügbarkeit prüfen

Impact of a specialised palliative care intervention in patients with advanced soft tissue sarcoma - a single-centre retrospective analysis

BMC palliative care, 2021-01, Vol.20 (1), p.16-9, Article 16

2021

Link zum Volltext

Verfügbarkeit prüfen

Chemotherapy in alveolar soft part sarcomas: What do we know?

European Journal of Cancer, 2003-07, Vol.39 (11), p.1511-1516

2003

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08)

Annals of oncology, 2018-06, Vol.29 (6), p.1386-1393

2018

Link zum Volltext

Verfügbarkeit prüfen

Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy

Annals of oncology, 2013-08, Vol.24 (8), p.2068-2073

2013

Link zum Volltext

Verfügbarkeit prüfen

Standardized and quality-assured predictive PD-L1 testing in the upper gastrointestinal tract

Journal of cancer research and clinical oncology, 2023-11, Vol.149 (17), p.16231-16238

2023

Link zum Volltext

Verfügbarkeit prüfen

The OUTREACH study: oncologists of German university hospitals in rotation on a palliative care unit—evaluation of attitude and competence in palliative care and hospice

Journal of cancer research and clinical oncology, 2023-07, Vol.149 (7), p.2929-2936

2023

Link zum Volltext

Verfügbarkeit prüfen

Reply to the letter to the editor ‘Anti-EGFR therapy in oesophagogastric cancer: precise but not enough’ by M. Salati and S. Cascinu

Annals of oncology, 2018-09, Vol.29 (9), p.2026-2026

2018

Link zum Volltext

Verfügbarkeit prüfen

Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): The randomized phase II INTEGA trial (AIO STO 0217)

Annals of oncology, 2018-10, Vol.29, p.viii265-viii266

2018

Link zum Volltext

Verfügbarkeit prüfen

Effects of a communication training for oncologists on early addressing palliative and end-of-life care in advanced cancer care (PALLI-COM): a randomized, controlled trial

ESMO open, 2022-12, Vol.7 (6), p.100623-100623, Article 100623

2022

Link zum Volltext

Verfügbarkeit prüfen

Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study

ESMO open, 2024-01, Vol.9 (1), p.102202-102202, Article 102202

2024

Link zum Volltext

Verfügbarkeit prüfen

Cisplatin/5-fluorouracil +/- panitumumab for patients with non-resectable, advanced or metastatic esophageal squamous cell cancer: A randomized phase III AIO/EORTC trial with an extensive biomarker program

Annals of oncology, 2018-06, Vol.29, p.v103-v103

2018

Link zum Volltext

Verfügbarkeit prüfen

Surgical results of patients after esophageal resection or extended gastrectomy for cancer of the esophagogastric junction

Diseases of the esophagus, 2009-08, Vol.22 (5), p.422-426

2009

Link zum Volltext

Verfügbarkeit prüfen

Patients’ perspectives towards malignant ascites: results of a prospective observational trial regarding expectations, characteristics and quality of life—a study of the North-Eastern-German Society of Gynecological Oncology

Archives of gynecology and obstetrics, 2019-05, Vol.299 (5), p.1385-1389

2019

Link zum Volltext

Verfügbarkeit prüfen

Metastatic gastric cancer: does second-line chemotherapy make sense?

Deutsche medizinische Wochenschrift (1946), 2010-09, Vol.135 (38), p.1872

2010

Link zum Volltext

Verfügbarkeit prüfen

2333 Trastuzumab in combination with different first-line chemotherapies for treatment of HER2-positive metastatic gastric or gastro- oesophageal junction cancer: Updated findings from the German non-interventional study HerMES

European journal of cancer (1990), 2015-09, Vol.51, p.S444-S444

2015

Link zum Volltext

Verfügbarkeit prüfen

German S3-guideline "Diagnosis and treatment of esophagogastric cancer"

Zeitschrift fur Gastroenterologie, 2011-04, Vol.49 (4), p.461

2011

Link zum Volltext

Verfügbarkeit prüfen

Pazopanib with 5‐FU and oxaliplatin as first line therapy in advanced gastric cancer: A randomized phase‐II study—The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO‐STO‐0510

International journal of cancer, 2022-03, Vol.150 (6), p.1007-1017

2022

Link zum Volltext

Verfügbarkeit prüfen

HER2 testing in gastric cancer - results of a German expert meeting

Zeitschrift fur Gastroenterologie, 2016-08, Vol.54 (8), p.791

2016

Link zum Volltext

Verfügbarkeit prüfen

Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis

European journal of cancer (1990), 2013-05, Vol.49 (7), p.1565-1577

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 107

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(93)
Mit Volltextzugriff
(100)

Publikationsform

Sprache

Englisch
(87)
Deutsch
(21)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Humans
(40)
Science & Technology
(39)
Life Sciences & Biomedicine
(38)
Oncology
(28)
Male
(22)
Female
(20)
Middle Aged
(20)
Adult
(17)
Aged
(17)
Treatment Outcome
(13)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(12)
Stomach Neoplasms - Pathology
(12)
Biological And Medical Sciences
(11)
Chemotherapy
(11)
Medical Sciences
(11)
Stomach Neoplasms - Drug Therapy
(11)
Adenocarcinoma - Drug Therapy
(9)
Disease-Free Survival
(9)
Follow-Up Studies
(9)
Medicine
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Cetuximab plus cisplatin–5-fluorouracil versus cisplatin–5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie

Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Multicenter phase II study of oral capecitabine (Xeloda“) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy

A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study

Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)

Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts

Impact of a specialised palliative care intervention in patients with advanced soft tissue sarcoma - a single-centre retrospective analysis

Chemotherapy in alveolar soft part sarcomas: What do we know?

Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08)

Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy

Standardized and quality-assured predictive PD-L1 testing in the upper gastrointestinal tract

The OUTREACH study: oncologists of German university hospitals in rotation on a palliative care unit—evaluation of attitude and competence in palliative care and hospice

Reply to the letter to the editor ‘Anti-EGFR therapy in oesophagogastric cancer: precise but not enough’ by M. Salati and S. Cascinu

Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): The randomized phase II INTEGA trial (AIO STO 0217)

Effects of a communication training for oncologists on early addressing palliative and end-of-life care in advanced cancer care (PALLI-COM): a randomized, controlled trial

Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study

Cisplatin/5-fluorouracil +/- panitumumab for patients with non-resectable, advanced or metastatic esophageal squamous cell cancer: A randomized phase III AIO/EORTC trial with an extensive biomarker program

Surgical results of patients after esophageal resection or extended gastrectomy for cancer of the esophagogastric junction

Patients’ perspectives towards malignant ascites: results of a prospective observational trial regarding expectations, characteristics and quality of life—a study of the North-Eastern-German Society of Gynecological Oncology

Metastatic gastric cancer: does second-line chemotherapy make sense?

2333 Trastuzumab in combination with different first-line chemotherapies for treatment of HER2-positive metastatic gastric or gastro- oesophageal junction cancer: Updated findings from the German non-interventional study HerMES

German S3-guideline "Diagnosis and treatment of esophagogastric cancer"

Pazopanib with 5‐FU and oxaliplatin as first line therapy in advanced gastric cancer: A randomized phase‐II study—The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO‐STO‐0510

HER2 testing in gastric cancer - results of a German expert meeting

Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis

Suchergebnisse filtern